文献速递乳房整形与再造

BREASTrial III期:脱细胞真皮基质乳房再造术后3个月至2年结局

The BREASTrial Stage III: Acellular Dermal Matrix Breast Reconstruction Outcomes from 3 Months to 2 Years Postoperatively.
PubMed 文献 · Plast Reconstr Surg · 2022-10-04

BREASTrial为盲法随机试验,比较AlloDerm与DermaMatrix在组织扩张器乳房再造中的结局。III期分析108例患者167侧乳房,两组总体并发症率(6% vs 13.2%;P=0.3)及严重程度(P=0.7)无差异,肥胖为并发症预测因素(P=0.02),患者满意度总体积极且两组相似。

要点

  • AlloDerm与DermaMatrix组总体并发症率无差异(6% vs 13.2%;P=0.3)。
  • 肥胖是并发症的预测因素(P=0.02),此类患者使用脱细胞真皮基质应谨慎。
  • 患者满意度总体积极,两组间无明显差异。

核心结论

  • AlloDerm与DermaMatrix在组织学和临床结局上相似,患者满意度亦相似;肥胖是并发症的预测因素,此类患者使用脱细胞真皮基质应谨慎。

研究设计与样本

  • 盲法随机对照试验,比较AlloDerm与DermaMatrix在组织扩张器乳房再造中的结局;随机入组128例患者(199侧乳房),III期分析纳入108例患者(167侧乳房)。

主要发现

  • AlloDerm组与DermaMatrix组总体并发症率无差异(6% vs 13.2%;P=0.3)。
  • 两组并发症严重程度无差异(P=0.7)。
  • 肥胖是并发症的阳性预测因素,与再造组别无关(P=0.02)。
  • 患者满意度总体积极,AlloDerm与DermaMatrix组间无明显差异。

临床怎么用

  • 作者认为肥胖是并发症的预测因素,此类患者使用脱细胞真皮基质应谨慎。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Breast Reconstruction Evaluation of Acellular Dermal Matrix as a Sling Trial (BREASTrial) is a blinded, randomized trial comparing the outcomes of tissue expander breast reconstruction using AlloDerm or DermaMatrix. In this final stage of the trial, outcomes 3 months to 2 years after definitive reconstruction are reported along with patient satisfaction data. METHODS: A randomized trial was conducted to compare complication rates between groups of patients who underwent reconstruction with AlloDerm and DermaMatrix. Regression models were used to analyze the impact of matrix type, age, chemotherapy, radiation therapy, and reconstructive type on complication rates. Premastectomy and postmastectomy questionnaires were used to assess patient satisfaction and were also analyzed using regression models. RESULTS: Of the 128 patients (199 breasts) who were randomized in the trial, 108 patients (167 breasts) were available for analysis in stage III. There was no difference in the overall complication rates between the AlloDerm and DermaMatrix groups (6% versus 13.2%; P = 0.3) or the severity of those complications ( P = 0.7). Obesity was a positive predictor for complications, regardless of reconstruction group ( P = 0.02). Patient satisfaction was positive overall and did not grossly vary between AlloDerm and DermaMatrix groups. CONCLUSIONS: Findings from the BREASTrial conclude that AlloDerm and DermaMatrix exhibit similar histologic and clinical outcomes. Patient satisfaction is also similar between matrices. Obesity is a predictor of complications, and acellular dermal matrices should be used with caution in these patients. As the largest head-to-head trial comparing two acellular dermal matrices, the BREASTrial contributes to the fund of knowledge regarding acellular dermal matrix supplementation in breast reconstruction. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Mendenhall SD, Moss WD, Graham EM, et al. The BREASTrial Stage III: Acellular Dermal Matrix Breast Reconstruction Outcomes from 3 Months to 2 Years Postoperatively. Plast Reconstr Surg. 2022. PMID: 36194057. doi:10.1097/PRS.0000000000009768

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。